IT之家 10 月 21 日消息,OpenAI 于当地时间周二宣布,收购成立四年的人工智能生物科技软件初创企业 Orchestra Bio,相关消息由该公司在官网发布。本次交易的具体条款并未对外披露,但有报道称,截至 2025 年,这家初创公司已从安德里森 · 霍罗威茨(Andreessen Horowitz)、阿特里亚(Atria)和 8VC 等投资方筹集约 2,000 万美元(IT之家注:现汇率约合 1.34 亿元人民币)资金。
Orchestra Bio 开发 AI 智能体,推动生物科技企业管理药物研发业务中的各类细碎工作,涵盖资金追踪,以及应对临床试验的排期难题。
OpenAI 表示,将吸纳 Orchestra Bio 的团队与工艺,投入 Rosalind 项目的研发。Rosalind 是该公司面向生命科学研究的人工智能模型,配套工具 Rosalind Workbench 可作为操作框架,协助科研人员外观实验、分析实验结果。OpenAI 称,Rosalind 已经拿下多家知名企业客户,其中涵盖莫德纳(Moderna)和诺和诺德(Novo Nordisk)。
这笔收购是一个典型案例,体现了头部人工智能实验室,也就是 OpenAI 与 Anthropic,正在为制药这类大型行业持续开发各类软件。初创行业一直存在一种担忧:这些大型实验室随时可能推出新能力,摇身一变成为竞争对手。而这一次,Orchestra Bio 是被收购整合,而非遭到碾压淘汰。
本文来源:https://www.ithome.com/1/015/621.htm
若有版权问题,请来信告知:13951431913#139.com 或在右方提交评论。
IT House October 21 news, OpenAI announced on Tuesday, local time, the acquisition of four years of artificial intelligence biotechnology software startup Orchestra Bio, related news released by the company on the official website. The terms of the deal were not disclosed, but it was reported that the startup had raised about $20 million from investors including Andreessen Horowitz, Atria and 8VC as of 2025.
Orchestra Bio develops AI agents that enable biotech companies to manage the fragmentation of their pharmaceutical R&D operations, including fund tracking and scheduling challenges for clinical trials.
OpenAI said that it will absorb the team and process of Orchestra Bio to invest in the research and development of the Rosalind project. Rosalind is the company's artificial intelligence model for life science research, and the supporting tool Rosalind Workbench can be used as an operational framework to assist researchers in appearance experiments and analysis of experimental results. Rosalind has secured a number of high-profile corporate clients, including Moderna and Novo Nordisk, according to OpenAI.
The acquisition is a classic example of the head AI labs, OpenAI and Anthropic, continuing to develop software for large industries like pharmaceuticals. There has been a concern in the startup industry that these large labs could launch new capabilities and become competitors at any time. This time, Orchestra Bio was acquired and consolidated, not rolled out.
This article is from: https://www.ithome.com/1/015/621.htm For copyright issues, please write to: 13951431913#139.com or submit a review on the right.